Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus

被引:5
作者
Hu, Zili [1 ,2 ]
Yang, Zhenyun [1 ,2 ]
Wang, Jiongliang [1 ,2 ]
Fu, Yizhen [1 ,2 ]
Hu, Zhiwen [1 ,2 ]
Zhou, Zhongguo [1 ,2 ]
Chen, Minshan [1 ,2 ]
Zhang, Yaojun [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Dept Liver Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
关键词
HCC; hepatocellular carcinoma; PVTT; portal vein tumor thrombus; HAIC; neoadjuvant hepatic arterial infusion chemotherapy; hepatoectomy; neoadjuvant therapy; C-REACTIVE PROTEIN; PHASE-II TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; CISPLATIN; LIVER; RADIOEMBOLIZATION; SORAFENIB; RESECTION; EFFICACY; SAFETY;
D O I
10.3389/fphar.2023.1223632
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background/purpose: The prognosis of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is generally poor and hepatectomy is optional for these patients. This study aims to explore the survival benefits of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) for resectable HCC with PVTT.Methods: This retrospective study included 120 resectable HCC patients with PVTT who underwent hepatectomy, from January 2017 to January 2021 at Sun Yat-sen University Cancer Center. Of these patients, the overall survival (OS) and recurrence-free survival (RFS) of 55 patients who received hepatectomy alone (Surgery group) and 65 patients who received neoadjuvant HAIC followed by hepatectomy (HAIC-Surgery group) were compared. Logistic regression analysis was conducted to develop a model predicting the response to neoadjuvant HAIC.Results: The OS rates for the HAIC-Surgery group at 1, 3, and 5 years were 94.9%, 78%, and 66.4%, respectively, compared with 84.6%, 47.6%, and 37.2% in the Surgery group (p < 0.001). The RFS rates were 88.7%, 56.2%, and 38.6% versus 84.9%, 38.3%, and 22.6% (p = 0.002). The subgroup analysis revealed that the survival benefit of neoadjuvant HAIC was limited to patients who responded to it. The logistic model, consisting of AFP and CRP, that predicted the response to neoadjuvant HAIC performed well, with an area under the ROC curve (AUC) of 0.756.Conclusion: Neoadjuvant HAIC followed by hepatectomy is associated with a longer survival outcome than hepatectomy alone for HCC patients with PVTT and the survival benefit is limited to patients who respond to neoadjuvant FOLFOX-HAIC.
引用
收藏
页数:14
相关论文
共 42 条
  • [1] A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
    Bruno, Peter M.
    Liu, Yunpeng
    Park, Ga Young
    Murai, Junko
    Koch, Catherine E.
    Eisen, Timothy J.
    Pritchard, Justin R.
    Pommier, Yves
    Lippard, Stephen J.
    Hemann, Michael T.
    [J]. NATURE MEDICINE, 2017, 23 (04) : 461 - +
  • [2] Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival
    Chung, Goh Eun
    Lee, Jeong-Hoon
    Kim, Hwi Young
    Hwang, Sang Youn
    Kim, Joon Suk
    Chung, Jin Wook
    Yoon, Jung-Hwan
    Lee, Hyo-Suk
    Kim, Yoon Jun
    [J]. RADIOLOGY, 2011, 258 (02) : 627 - 634
  • [3] Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model
    Dzodic, R
    Gomez-Abuin, G
    Rougier, P
    Bonnay, M
    Ardouin, P
    Gouyette, A
    Rixe, O
    Ducreux, M
    Munck, JN
    [J]. ANTI-CANCER DRUGS, 2004, 15 (06) : 647 - 650
  • [4] EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
  • [5] 2-E
  • [6] Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-α for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis
    Eun, Jong Ryul
    Lee, Heon Ju
    Moon, Hee Jung
    Kim, Tae Nyeun
    Kim, Jae Woon
    Chang, Jay Chun
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (12) : 1477 - 1486
  • [7] Hepatocellular carcinoma
    Forner, Alejandro
    Reig, Maria
    Bruix, Jordi
    [J]. LANCET, 2018, 391 (10127) : 1301 - 1314
  • [8] Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Shimada, Noritomo
    Kawata, Kazuhito
    Kosaka, Hisashi
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Naganuma, Atsushi
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    Kumada, Takashi
    [J]. HEPATOLOGY INTERNATIONAL, 2022, 16 (05) : 1150 - 1160
  • [9] Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis
    He, Min-Ke
    Zou, Ru-Hai
    Li, Qi-Jiong
    Zhou, Zhong-Guo
    Shen, Jing-Xian
    Zhang, Yong-Fa
    Yu, Zi-Shan
    Xu, Li
    Shi, Ming
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (05) : 734 - 743
  • [10] Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized
    He, Min-Ke
    Le, Yong
    Li, Qi-Jiong
    Yu, Zi-Shan
    Li, Shao-Hua
    Wei, Wei
    Guo, Rong-Ping
    Shi, Ming
    [J]. CHINESE JOURNAL OF CANCER, 2017, 36